All India Institute of Ayurveda, New Delhi has announced their collaboration with Nisarga Biotech Pvt Ltd, parent company of Nisarga Herbs to conduct a double-blind, randomised, placebo controlled trial at ESIC Medical College and Hospital, Faridabad. Prof. (Dr.) Tanuja Nesari, MD, PhD, Director of AIIA, will be the Principal Investigator and Dr. Asim Sen, Dean ESIC medical college and hospital, Faridabad will be the co-investigator along with team of 6 doctors from AIIA and ESIC. Nisarga is the first Indian Ayurveda company to work with AIIA, who will study their proprietary neem extract formulation for the prevention of Covid-19 in 250 subjects. The study entitled ‘Prophylaxis with Neem Capsules (Azadirachta Indica) in Healthcare Personnel and Relatives in Contact with COVID-19 Patients’ is designed primarily to evaluate the preventative effect of neem capsules in subjects coming in contact with COVID- 19 patients.
The first step of recruitment for this Human trials has already started from 7th August wherein the formulation will be tested and studied on 250 individuals and this would be a double-blind trial where 125 patients would be using their proprietary Neem capsules while the other 125 would be taking blank capsules for 28 days. The drug will be administered for 28 days followed by the observation period of 28 days and check the effect of the capsules in comparison with the blank capsules. Meaning of double blind is neither the doctor nor the patient knows if he is taking Neem or blank capsules. So any bias in evaluation of effect of Neem is eliminated.
Speaking about it, Girish Soman, Founder and CEO of Nisarga Biotech Pvt Ltd said, “There may be some big companies carrying out clinical trials through ayurvedic formulations but Nisarga is the first manufacturer to conduct this trial with its own funds in collaboration with India’s apex Ayurveda Hospital and Institute, All India Institute of Ayurveda is known for researching Ayurveda in a modern way. Our Neem formulation will prove to be an effective antiviral in preventive use, and we are looking at strategic funding for further research to introduce it as a standard drug.”
- CDC Broadens Definition of ‘Close Contact’ in Tracing COVID Infections - October 22, 2020
- P&G Sets New Goal to Deliver 25 Billion Liters of Clean Drinking Water to Families in Need Worldwide - October 22, 2020
- Apollo Pharmacy Walk In 23rd Oct 2020 for BPharm MPharm DPharm Freshers - October 22, 2020
- कार्यालयों में अब होगी शत-प्रतिशत कर्मचारियों की उपस्थिति - October 22, 2020
- India’s Contribution Will Be Critical In Fighting Covid: Health Minister - October 22, 2020
- COVID-19 Vaccine Trial Will Continue, Says Oxford After Volunteer Dies - October 22, 2020
- Amazon To Let Employees Work From Home Till June 2021 - October 22, 2020
- India’s Serum Institute, Partners Join Race To Develop COVID-19 Treatment - October 22, 2020
- AstraZeneca COVID-19 Vaccine Trial Volunteer Dies, Says Brazil - October 22, 2020
- 55,839 Fresh Coronavirus Cases In India, Total Cases At 77.06 Lakh - October 22, 2020